John L. Berk, MD
Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, Case Western Reserve University
BA, Wesleyan University



Expertise in Amyloidosis with specific emphasis in Familial and localized amyloid disease; pulmonary fibrosis.

Member
Boston University
Pulmonary Center


Assistant Director
Boston University
Amyloidosis Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences




An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
11/21/2024 - 11/21/2027 (PI)
Alnylam Pharmaceuticals, Inc.


ALXN2220-ATTRCM-301, D6810C00001 A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants wit
05/03/2024 - 05/03/2027 (PI)
Alexion Pharmaceuticals, Inc.


An Open-Label Extension Study to Assess the Long-Term Safety of Eplontersen (ION-682884) in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) ION682884-CS12
12/20/2023 - 12/20/2026 (PI)
Ionis Pharmaceuticals, Inc.


ALN-TTR02-013: ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR amyloidosis)
09/22/2021 - 09/22/2026 (PI)
Alnylam Pharmaceuticals, Inc.


Protocol ALN-TTR02-014: Expanded Access Protocol to provide Patisiran to Patients with Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) with Cardiomyopathy
06/16/2022 - 06/16/2025 (PI)
Alnylam Pharmaceuticals, Inc.


A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients with Familial Amyloidollo Polyneuropathy Who Have
02/04/2014 - 02/28/2025 (PI)
Alnylam Pharmaceuticals, Inc.


Protocol ION-682884-CS2: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomy
03/20/2020 - 11/19/2024 (Subcontract PI)
Pharmaceutical Research Associates, Inc. IonisPharmaceuticals


Protocol # ION-682844-CS3: A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
11/15/2019 - 09/16/2024 (Subcontract PI)
Pharmaceutical Research Associates, Inc. IonisPharmaceuticals


"ALN-TTR02-011, APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Car
09/12/2019 - 09/12/2024 (PI)
Alnylam Pharmaceuticals, Inc.


[ION-682884-CS13]: An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
09/28/2021 - 08/03/2024 (PI)
Ionis Pharmaceuticals, Inc.


Showing 10 of 36 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs
2009 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-05 9
2008 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-04 9
2007 THE EFFECT OF DIFLUNISAL ON HEREDITARY AMYLOIDOSIS 2M01RR000533-39-8163 503
2007 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-03 9
2007 Effect of diflunisal on familial amyloidosis 5R01FD002532-03 2
2006 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-02 9
2006 Effect of diflunisal on familial amyloidosis 5R01FD002532-02 2
2005 Effect of diflunisal (IND68092) on familial amyloidosis 1R01NS051306-01 9
2001 ADRENAL INSUFFICIENCY IN PRIMARY SYSTEMIC AMYLOIDOSIS 5M01RR000533-33-353 503
2000 ADRENAL INSUFFICIENCY IN PRIMARY SYSTEMIC AMYLOIDOSIS 5M01RR000533-32-353 503
Showing 10 of 15 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L. Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. JAMA Neurol. 2025 Mar 01; 82(3):228-236. PMID: 39804640; PMCID: PMC11894486; DOI: 10.1001/jamaneurol.2024.4631;
     
  2. Conceição I, Berk JL, Weiler M, Kowacs PA, Dasgupta NR, Khella S, Chao CC, Attarian S, Kwoh TJ, Jung SW, Chen J, Viney NJ, Yu RZ, Gertz M, Masri A, Cruz MW, Coelho T. Correction: Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. J Neurol. 2025 Feb 03; 272(2):182. PMID: 39899052; PMCID: PMC11790725; DOI: 10.1007/s00415-024-12854-8;
     
  3. Wixner J, Berk JL, Adams D, Polydefkis M, Conceição I, Attarian S, Gillmore JD, Dyck PJB, Folkvaljon F, Zhou W, Chen J, Viney NJ, Kwoh TJ, Coelho T, Waddington-Cruz M. Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial. Amyloid. 2025 Mar; 32(1):29-38. PMID: 39552152
     
  4. Folkvaljon F, Gertz M, Gillmore JD, Khella S, Masri A, Maurer MS, Cruz MW, Wixner J, Chen J, Reicher B, Kwoh J, Yarlas A, Berk JL. Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health-Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis. Muscle Nerve. 2025 Jan; 71(1):96-107. PMID: 39552102; PMCID: PMC11632571; DOI: 10.1002/mus.28299;
     
  5. Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, González-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025 Jan 02; 392(1):33-44. PMID: 39213194
     
  6. Conceição I, Berk JL, Weiler M, Kowacs PA, Dasgupta NR, Khella S, Chao CC, Attarian S, Kwoh TJ, Jung SW, Chen J, Viney NJ, Yu RZ, Gertz M, Masri A, Cruz MW, Coelho T. Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. J Neurol. 2024 Oct; 271(10):6655-6666. PMID: 39138650; PMCID: PMC11447117; DOI: 10.1007/s00415-024-12616-6;
     
  7. Luigetti M, Quan D, Berk JL, Conceição I, Misumi Y, Chao CC, Bender S, Aldinc E, Vest J, Adams D. Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study. Neurol Ther. 2024 Jun; 13(3):625-639. PMID: 38512694; PMCID: PMC11136903; DOI: 10.1007/s40120-024-00595-9;
     
  8. Garcia-Pavia P, Grogan M, Kale P, Berk JL, Maurer MS, Conceição I, Di Carli M, Solomon SD, Chen C, Yureneva E, Vest J, Gillmore JD. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail. 2024 Feb; 26(2):397-410. PMID: 38321786
     
  9. Lau KHV, Prokaeva T, Zheng L, Doros G, Kaku MC, Spencer B, Berk J, Sanchorawala V. Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis. Amyloid. 2024 Jun; 31(2):150-152.View Related Profiles. PMID: 38073425
     
  10. Masri A, Maurer MS, Claggett BL, Kulac I, Waddington Cruz M, Conceição I, Weiler M, Berk JL, Gertz M, Gillmore JD, Rush S, Chen J, Zhou W, Kwoh J, Duran JM, Tsimikas S, Solomon SD. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. J Card Fail. 2024 Aug; 30(8):973-980. PMID: 38065307
     
Showing 10 of 129 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 129 publications over 30 distinct years, with a maximum of 13 publications in 2022

YearPublications
19871
19911
19931
19942
19962
19983
19993
20002
20012
20023
20032
20043
20054
20071
20101
20117
20125
20135
20144
20157
20164
201710
201811
20197
20209
20213
202213
20235
20246
20252

2019 Boston Top Doctors
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

amyloid lung disease
amyloidosis
familial amyloidotic polyneuropathy
pleural effusions
pulmonary fibrosis
tracheobronchial amyloidosis
Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Berk's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department